## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

#### HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Guidance development**

# STA aflibercept for treating myopic choroidal neovascularisation

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Have the potential equality issues identified during the scoping

### Final appraisal determination

(when no ACD was issued)

1.

During the scoping process it was noted that myopic choroidal neovascularisation is more common in people of Asian family origin. However, issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

2.	Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No.	
3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No.	

Technology appraisals: Guidance development

4.	Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.	
5.	Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.	
7.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No equality issues were raised during the appraisal.	
Approved by Programme Director (name):Frances Sutcliffe  Date: 25/08/2017	

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of aflibercept for treating myopic choroidal neovascularisation 2 of 2

Issue date: September 2017